510(k) Report

510(k) · Cleared

Cleared

DSM Biomedical Calcium Phosphate Cement

K173362510(k) TraditionalCleared Apr 3, 2018159-day reviewClass II21 CFR 888.3045

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Kensey Nash Corporation Dba Dsm Biomedical · MQV Filler, Bone Void, Calcium Compound

Cleared on Apr 3, 2018 as substantially equivalent to K060061 (Stryker Corp., 2006) after a 159-day review. Its family tree reaches back 8 generations to 1987. 3 later devices descend from it.

Decided
Apr 3, 2018
Review
159 days
Class
Class II
Product code
MQV
Recalls
None
Predicates
1

Its longest line of descent runs back 8 generations to K873689 (1987). 18 ancestors in all, the oldest K861369 (1986). 3 later devices descend from it, 2 citing it directly.

  1. Root · 8 generations backK873689 Cranioplastic, Acrylic Cranioplasty MaterialDentsply Intl. · 1987
  2. 7 generations backK953339 Bonesource Hydroxyapatite Cement (Hac)Osteogenics, Inc. · 1996
  3. 6 generations backK973789 Norian Cranial Repair System (CRS)Bone Cement- 5CC Kit, Norian…Norian Corp. · 1998
  4. 5 generations backK991398 Bonesource Hydroxyapatite Cement (Hac) Expanded KitStryker Leibinger · 1999
  5. 4 generations backK021440 Bonesource HacStryker Instruments · 2002
  6. 3 generations backK032366 Bonesource Hac Fast Setting CementStryker Instruments · 2003
  7. 2 generations backK043334 Bone Source Hac Rapid Setting CementStryker Instruments · 2005
  8. 1 generation backK060061 Stryker Injectable CementStryker Corp. · 2006
  9. This deviceK173362 DSM Biomedical Calcium Phosphate CementKensey Nash Corporation Dba Dsm Biomedical · 2018
  10. Descendant · cites it directly · 1 of its ownK212991 OsteoreviveBone Solutions, Inc. · 2022
  11. Descendant · cites it directly · 0 of its ownK230054 DSM Biomedical Calcium Phosphate CementDsm Biomedical · 2023
  12. Descendant · 2 generations on · 0 of its ownK221256 Mg OSTEOINJECTBone Solutions, Inc. · 2022

Most influential descendants

Showing 3 of 3 · See all
  • K212991OsteoreviveBone Solutions, Inc. · 2022 · cites it directly1descendant
  • K230054DSM Biomedical Calcium Phosphate CementDsm Biomedical · 2023 · cites it directly0descendants
  • K221256Mg OSTEOINJECTBone Solutions, Inc. · 2022 · 2 generations on0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−8K873689Cranioplastic, Acrylic Cranioplasty MaterialDentsply Intl.1987—
−7K953339Bonesource Hydroxyapatite Cement (Hac)Osteogenics, Inc.1996—
−6K973789Norian Cranial Repair System (CRS)Bone Cement- 5CC Kit, Norian Cranial Repair…Norian Corp.1998—
−5K991398Bonesource Hydroxyapatite Cement (Hac) Expanded KitStryker Leibinger1999—
−4K021440Bonesource HacStryker Instruments2002—
−3K032366Bonesource Hac Fast Setting CementStryker Instruments2003—
−2K043334Bone Source Hac Rapid Setting CementStryker Instruments2005—
−1K060061Stryker Injectable CementStryker Corp.2006—
0 (this device)K173362DSM Biomedical Calcium Phosphate CementKensey Nash Corporation Dba Dsm Biomedical2018—
+1K212991OsteoreviveBone Solutions, Inc.2022—
+1K230054DSM Biomedical Calcium Phosphate CementDsm Biomedical2023—
+2K221256Mg OSTEOINJECTBone Solutions, Inc.2022—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
198610
199210
199720
199910
200120
200210
200310
200410

Descendants by year cleared

Year clearedDevicesWith a Class I recall
202220
202310
FIG. 1 — Lineage of K173362, 1987–2023Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in MQV? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new MQV device

  1. #1 K232315 Catalyst Bone Void Fillerscore 25.2 · 25 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K060061Stryker Injectable Cement
Summary page 4
…, Drillable, Non-screw Augmentation Advisory Panel: Orthopedic Predicate Device: Stryker® Injectable Cement (K060061) [Stryker® CMF] Device Description DSM Biomedical Calcium Phosphate Cement as an injectable, sculptable, fast self…
Stryker Corp.2006—

Also cleared against K060061: 6 other devices →

What descends from it? (3)

2 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K212991OsteoreviveBone Solutions, Inc.20221
K230054DSM Biomedical Calcium Phosphate CementDsm Biomedical20230

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 31 years and passes through 7 companies; a new generation was cleared every 1.9 years on median.
  • 1 of the 18 ancestors has a recall of any class.
  • Of its descendants, K212991 (Bone Solutions, Inc., 2022) has gone furthest, with 1 descendant of its own.
  • 6 other devices also cite its predicate K060061.

How does its category compare?

All MQV devices

MQV Filler, Bone Void, Calcium Compound: FDA decisions, review times, recalls and adverse event reports over 20 years. 2018, this device’s year, is highlighted.

FDA decisions per year · MQV

14in 2025

2007: 352008: 322009: 232010: 172011: 162012: 92013: 122014: 202015: 182016: 82017: 172018: 232019: 132020: 152021: 82022: 92023: 212024: 282025: 142026 (partial year): 5
2007high 35 (2007) · low 8 (2016)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · MQV

57in 2025

2007: 144 days median2008: 102 days median2009: 180 days median2010: 147 days median2011: 92 days median2012: 107 days median2013: 197 days median2014: 153 days median2015: 184 days median2016: 214 days median2017: 124 days median2018: 124 days median2019: 90 days median2020: 132 days median2021: 88 days median2022: 118 days median2023: 74 days median2024: 55 days median2025: 57 days median2026 (partial year): 96 days median
2007high 214 (2016) · low 55 (2024)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · MQV

1in 2025

2007: 52008: 32009: 12011: 62012: 32013: 22016: 12017: 12018: 22020: 12023: 32024: 22025: 12026 (partial year): 4
2007high 6 (2011) · low 0 (2010)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · MQV

57in 2025

2007: 672008: 712009: 812010: 682011: 1142012: 1492013: 2232014: 1112015: 1252016: 1062017: 1072018: 862019: 652020: 1262021: 1012022: 472023: 1202024: 682025: 57
2007high 223 (2013) · low 47 (2022)2025

MAUDE reports naming product code MQV, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
200735144567
200832102371
200923180181
201017147068
201116926114
201291073149
2013121972223
2014201530111
2015181840125
201682141106
2017171241107
201823124286
20191390065
2020151321126
20218880101
20229118047
202321743120
20242855268
20251457157
20265964—

What is it indicated for?

DSM Biomedical Calcium Phosphate Cement is indicated to fill bony voids or gaps of the skeletal system (i.e. extremities and pelvis). These defects may be surgically created or osseous defects created from traumatic injury to the bone. The DSM Biomedical Calcium Phosphate Cement is indicated only for bony voids or gaps that are not intrinsic to the stability of the bony structure. The DSM Biomedical Calcium Phosphate Cement cured in situ provides an open…

Read the full statement (130 words)

DSM Biomedical Calcium Phosphate Cement is indicated to fill bony voids or gaps of the skeletal system (i.e. extremities and pelvis). These defects may be surgically created or osseous defects created from traumatic injury to the bone. The DSM Biomedical Calcium Phosphate Cement is indicated only for bony voids or gaps that are not intrinsic to the stability of the bony structure. The DSM Biomedical Calcium Phosphate Cement cured in situ provides an open void/gap filler that can augment provisional hardware (e.g. K-Wires, plates, screws) to help support bone fragments during the surgical procedure. The cured cement acts only as a temporary support media and is not intended to provide structural support during the healing process. The Calcium Phosphate Cement resorbs and is replaced by bone during the healing process.

Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K173362: DSM Biomedical Calcium Phosphate Cement.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K173362

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026